Abbott Laboratories (ABT) – Double-digit growth in growth drivers – FreeStyle Libre, MitraClip and Alinity

Abbott delivered strong Q1FY19 performance with 2% growth in revenues on reported basis and 7.1% growth in revenues on an organic basis. The growth was due to double-digit growth in FreeStyle Libre, MitraClip and Alinity. The adjusted EPS grew by 6.8% to $0.63 in Q1FY19

Number of pages – 41

Content:

Executive Summary………………………………………………………..1

Financial Statements

–Income Statement and Forecast……………………………..…………..5

–Balance Sheet………………………………………………………………6

–Cash Flow……………………………………………………………………7

–Q1FY19 Results – Overview………………………………………………8

–Q1FY19 – Segment Performance……..……………….…………….….10

–FY19 – Guidance…………………….…..…………………………..……16

–Conclusion………………………………………………………………….17

–GAAP to Non-GAAP Reconciliation…..………………………….…..…18

Historical Performance

–Key Ratios………………………………………………………………….20

–Profitability Ratios, Asset Turnover Ratio, Growth Ratio…………..….21

–Per Share Items and Key Ratios……………………………….……..…23

–Key Cash Flow Items……………………………………………….…….24

–P/E Band……………………………………………………………………25

Product Performance and Key Developments

–Ownership……………………………………………………………….…27

–Competition………………………………………………………………..28

–Key Developments………………………………………………………..29

Valuation and Consensus Performance

–Relative Valuation…………………………………………………………31

–Analyst Recommendations…………………………….………….…..…34

Market Price Performance……………………………………………….36